Frequently Asked Questions
Factors such as increased strategic collaborations and initiatives and growing healthcare facilities are acting as the major drivers for the global vaginal anti infectives market.
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Perrigo Company plc (U.S.).
The major countries covered in the global vaginal anti infectives market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
